Patients with MSI-H/dMMR LARC have distinct clinicopathological and molecular features, including higher tumor-infiltrating lymphocytes and overexpression of immune checkpoint receptors like programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), making them particularly sensitive to immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.